Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
GEN1106 · 1 trial · 2 indications
| Name | Type | Description |
|---|---|---|
| GEN1106 | BIOLOGICAL | Intravenous (IV) infusion. |
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
GEN1106 is an investigational monoclonal antibody being studied for the treatment of solid tumors, including urothelial carcinoma. It is currently in Phase 1 clinical development for oncology indications.
GEN1106 is being developed by Genmab A/S, a biopharmaceutical company listed on the Nasdaq under the ticker GMAB. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with solid tumors.
GEN1106 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still being studied in clinical trials to assess its safety and potential efficacy in treating solid tumors.
GEN1106 is being evaluated in a Phase 1 clinical trial with the identifier NCT07416123, titled 'A Study of GEN1106 in Participants With Solid Tumors.' The trial is currently recruiting participants and has an estimated enrollment of 103 patients with solid tumors, including urothelial carcinoma.
Yes, GEN1106 is a monoclonal antibody, a type of biologic drug designed to target specific proteins involved in disease. It is being investigated as a potential treatment for solid tumors, including urothelial carcinoma.